Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

NBSE
NeuBase Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive
May 10, 2024
0.3780USD-3.201%(-0.0125)97,744
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-0.39)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
08:36AM EST  The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In   Benzinga
Jan 10, 2022
04:02PM EST  NeuBase Therapeutics Names Todd Branning CFO   Benzinga
04:02PM EST  NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer   GlobeNewswire Inc
Jan 5, 2022
04:02PM EST  NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors   GlobeNewswire Inc
Dec 23, 2021
04:02PM EST  NeuBase Therapeutics Reports FY21 EPS $(0.93) Down From $(0.89) YoY   Benzinga
04:01PM EST  NeuBase Therapeutics Reports Business Update and Financial Results   GlobeNewswire Inc
Nov 24, 2021
12:39PM EST  EXCLUSIVE: NeuBase Therapeutics Chairman & CEO, Dietrich Stephan, PhD Now Interviewing On Benzinga' Live Tv   Benzinga
11:31AM EST  EXCLUSIVE: NeuBase Therapeutics Chairman & CEO, Dietrich Stephan, PhD To Appear On Benzinga' Live Tv At 12:15 p.m. ET   Benzinga
Oct 5, 2021
08:00AM EDT  VBL Therapeutics Announces Appointment of Sam Backenroth as Chief   GlobeNewswire Inc
Sep 28, 2021
04:15PM EDT  NeuBase Therapeutics To Present At Chardan Genetic Medicines Conference Oct. 5 At 11:30 a.m. EDT   Benzinga
04:05PM EDT  NeuBase to Participate at the Chardan 5th Annual Genetic Medicines   GlobeNewswire Inc
Sep 15, 2021
04:05PM EDT  NeuBaseto Present at theOppenheimer Fall   GlobeNewswire Inc
Sep 14, 2021
08:00AM EDT  NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief   GlobeNewswire Inc
Sep 1, 2021
04:05PM EDT  NeuBase Therapeutics to Present Virtually at the H.C. Wainwright   GlobeNewswire Inc
Aug 12, 2021
04:21PM EDT  NeuBase Therapeutics Q3 EPS $(0.29) Down From $(0.18) YoY   Benzinga
04:01PM EDT  NeuBase Therapeutics Reports Financial Results for the Third   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
11:23AM EDT  NeuBase Therapeutics Option Alert: Feb 18 $5 Calls Sweep (17) near the Ask: 414 @ $1.15 vs 23 OI; Earnings 8/12 After Close [est] Ref=$4.27   Benzinga
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 23, 2021
05:25PM EDT  NeuBase Therapeutics Files Prospectus To Resale From Time To Time By Selling Stockholder Of Up To 308,635 Shares Of Common Stock   Benzinga
Jun 8, 2021
12:30PM EDT  NeuBase Therapeutics Says Demonstrates Functional Rescue In Myotonic Dystrophy Type 1 Model And Allele-Selective Inhibition Of KRAS Mutations To Inhibit Tumor Growth   Benzinga
12:30PM EDT  NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic   GlobeNewswire Inc
Jun 2, 2021
09:00AM EDT  NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking   GlobeNewswire Inc
Jun 1, 2021
06:42AM EDT  HC Wainwright & Co. Maintains Buy on NeuBase Therapeutics, Lowers Price Target to $15   Benzinga
May 25, 2021
08:00AM EDT  NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business   GlobeNewswire Inc
May 20, 2021
08:00AM EDT  NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical   GlobeNewswire Inc
May 14, 2021
12:31PM EDT  RBC Capital Markets Virtual Global Healthcare Conference Fireside Chatat 11:30 a.m. ET on May 19   GlobeNewswire Inc
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
04:46PM EDT  NeuBase Therapeutics Q2 EPS $(0.24) Up From $(0.26) YoY   Benzinga
04:05PM EDT  NeuBase Therapeutics Reports Financial Results for the Second   GlobeNewswire Inc
May 12, 2021
09:00AM EDT  NeuBase Therapeutics Appoints Gerald J. McDougall to Board of   GlobeNewswire Inc
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
Apr 27, 2021
08:00AM EDT  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (NeuBase), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the B. Riley Securities Virtual Neuroscience Conference being held on April 28 - 29.   GlobeNewswire Inc
Apr 26, 2021
04:01PM EDT  NeuBase Therapeutics Announces Closing of Public Offering and Full   GlobeNewswire Inc
Apr 23, 2021
07:28AM EDT  The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs   Benzinga
Apr 22, 2021
09:08AM EDT  NeuBase Therapeutics Prices 8M Share Common Stock Offering At $5/Share   Benzinga
09:07AM EDT  NeuBase Therapeutics Announces Pricing of $40 Million Public   GlobeNewswire Inc
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 21, 2021
04:04PM EDT  NeuBase Therapeutics Announces A Common Stock Offering; No Terms Disclosed   Benzinga
04:01PM EDT  NeuBase Therapeutics Announces Proposed Public Offering of Common   GlobeNewswire Inc
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
10:18AM EDT  Stocks That Hit 52-Week Lows On Monday   Benzinga
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
07:00AM EDT  Coya Therapeutics Announces the Appointment of   GlobeNewswire Inc
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 8, 2021
08:14AM EDT  The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data   Benzinga
08:00AM EDT  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it will host a virtual R&D day for investors and analysts on Tuesday, June 8, 2021, from 12:30 p.m. to 2:30 p.m. EDT.   GlobeNewswire Inc
Mar 16, 2021
08:00AM EDT  NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy   GlobeNewswire Inc
Mar 9, 2021
07:00AM EST  NeuBase Therapeutics to Present at Upcoming Investor Conferences   GlobeNewswire Inc
Feb 12, 2021
06:52AM EST  HC Wainwright & Co. Maintains Buy on NeuBase Therapeutics, Raises Price Target to $18   Benzinga
Feb 11, 2021
04:05PM EST  NeuBase Therapeutics Q1 EPS $(0.18) Up From $(0.26) YoY   Benzinga
04:01PM EST  Recently demonstrated single-dose intravenous administration of a PATrOL-enabled compound resolves the causal genetic defect in myotonic dystrophy type 1 (DM1) in transgenic animals; Company on course to move one program into clinical development in CY2022   GlobeNewswire Inc
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Jan 28, 2021
08:03AM EST  NeuBase Therapeutics Announces Acquisition Of Gene Modulating Technology From Vera Therapeutics; Terms Not Disclosed   Benzinga
08:00AM EST  Acquisition includes intellectual property for peptide nucleic acid genetic medicine portfolio that has demonstrated in vivo activity in several disease indications   GlobeNewswire Inc
Jan 22, 2021
08:38AM EST  Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 22, 2021: TWTR, CLII, NBSE, GIK, WBAI   Benzinga
Jan 21, 2021
12:20PM EST  David Einhorn Notorious Tesla Short Seller Just Had His Best Quarter Ever   Benzinga
Jan 11, 2021
06:00AM EST  NeuBase Therapeutics to Present at the H.C. Wainwright Virtual   GlobeNewswire Inc
Dec 23, 2020
04:07PM EST  NeuBase Therapeutics Reports FY20 EPS $(0.89) Compared To $(3.16) In The Prior Year   Benzinga
04:05PM EST  Data presented throughout 2020 have validated the potential of the PATrOL platform to develop highly targeted therapies that increase, decrease or change causal protein function   GlobeNewswire Inc
Dec 16, 2020
06:52AM EST  NeuBase Therapeutics Reports Positive Preclinical In Vivo Data For PATrOL-Enabled Anti-Gene For Treatment Of Myotonic Dystrophy Type 1   Benzinga
06:38AM EST  NeuBase Announces Positive Preclinical In Vivo Data For PATrOL-enabled Anti-gene For Myotonic Dystrophy Type 1   RTTNews
06:30AM EST  In vivo data after single-dose IV administration demonstrate engagement with DMPK mRNA and broad rescue of mis-splicing across key transcripts   GlobeNewswire Inc
Dec 2, 2020
08:00AM EST  NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D.   GlobeNewswire Inc
Nov 23, 2020
08:00AM EST  NeuBase Therapeutics to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Nov 17, 2020
08:00AM EST  NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D.   GlobeNewswire Inc
Nov 10, 2020
08:00AM EST  NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference being held on November 16 - 18.   GlobeNewswire Inc
Oct 13, 2020
08:00AM EDT  NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D.,   GlobeNewswire Inc
Sep 28, 2020
08:00AM EDT  NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the Chardan Virtual 4TH Annual Genetic Medicines Conference being held on October 5 - 6.   GlobeNewswire Inc
Sep 17, 2020
08:30AM EDT  NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced that Dietrich A. Stephan, Ph.D., chief executive officer, is scheduled to present at the Myotonic Dystrophy Foundation 2020 Virtual Conference on September 25 between 4:00 p.m. and 4:45 p.m. ET.   GlobeNewswire Inc
Sep 8, 2020
08:00AM EDT  22nd Annual H.C. Wainwright Global Investor Conference presentation at1:30 p.m. ET on September 16TH   GlobeNewswire Inc
Aug 13, 2020
04:06PM EDT  NeuBase Therapeutics Q3 EPS $(0.18) Up From $(0.38) YoY   Benzinga
04:01PM EDT  Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic Medicines   GlobeNewswire Inc
Jul 28, 2020
08:01AM EDT  NeuBase Therapeutics Strengthens Senior Management Team with   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC